Equities research analysts forecast that Vaccinex Inc (NASDAQ:VCNX) will announce earnings of ($0.70) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Vaccinex’s earnings. The business is scheduled to announce its next quarterly earnings report on Wednesday, August 21st.
On average, analysts expect that Vaccinex will report full year earnings of ($2.35) per share for the current fiscal year, with EPS estimates ranging from ($2.48) to ($2.21). For the next financial year, analysts anticipate that the firm will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.29) to ($1.73). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Vaccinex.
Vaccinex (NASDAQ:VCNX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.04). The business had revenue of $0.09 million during the quarter.
Separately, Zacks Investment Research reiterated a “hold” rating on shares of Western New England Bancorp in a research note on Saturday, June 29th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $17.58.
An institutional investor recently raised its position in Vaccinex stock. Telemetry Investments L.L.C. grew its holdings in Vaccinex Inc (NASDAQ:VCNX) by 26.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,720 shares of the company’s stock after buying an additional 3,066 shares during the quarter. Telemetry Investments L.L.C. owned approximately 0.13% of Vaccinex worth $54,000 at the end of the most recent reporting period. Institutional investors own 1.57% of the company’s stock.
Vaccinex stock traded down $0.17 during mid-day trading on Friday, hitting $4.15. 3,000 shares of the company were exchanged, compared to its average volume of 7,393. The business has a fifty day moving average of $5.67. Vaccinex has a 1-year low of $3.32 and a 1-year high of $12.00. The company has a market capitalization of $47.64 million and a P/E ratio of -0.80.
Vaccinex Company Profile
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Featured Story: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.